COMP360 Psilocybin: Pivotal Claims Outpace Verified Evidence, Blinding Risk Looms

Compass Pathways' COMP360 Nears FDA Approval for TRD

Compass Pathways' psilocybin-based candidate, COMP360, is nearing potential FDA approval for treatment-resistant depression (TRD), with analysts predicting a 75-85% chance of approval by the end of 2026 and a possible launch by the first half of 2027. The company has successfully completed two "highly statistically significant" Phase 3 trials, demonstrating a strong clinical effect. COMP360 is currently undergoing a rolling submission to the FDA and has received a Commissioner’s National Priority Voucher, positioning it as a leading psychedelic therapeutic on the cusp of market entry.

• COMP360 has demonstrated "highly statistically significant" clinical effects in two Phase 3 trials for treatment-resistant depression (TRD), a condition historically difficult to treat. This robust data forms the basis for its anticipated regulatory success, validating the therapeutic potential of psilocybin in this patient population.
• Compass Pathways is pursuing a rolling submission to the FDA for COMP360, with analysts projecting a 75-85% likelihood of approval by the end of 2026 and a market launch by the first half of 2027. The candidate has also been granted a Commissioner’s National Priority Voucher, potentially expediting its review and market access.
• If approved, COMP360 will enter a market with existing treatments like Johnson & Johnson’s Spravato, which, while not a traditional psychedelic, has paved the way for novel therapies in TRD. COMP360's potential approval would mark a significant milestone for psychedelic medicine, offering a new treatment paradigm for patients with severe depression.

Addressing Key Challenges in Treatment-Resistant Depression

Treatment-resistant depression (TRD) presents a complex clinical landscape where a substantial proportion of patients fail to achieve remission despite multiple adequate antidepressant trials. The evidence base for guiding "next step" treatment decisions remains limited in quality and scope, complicating both clinical and strategic planning. Several distinct challenges define the current state of TRD management.

• Insufficient evidence for pharmacological sequencing. A Cochrane review of 10 RCTs (2,731 participants) found that augmenting current antidepressant therapy with antipsychotics (cariprazine, olanzapine, quetiapine, or ziprasidone) improves depressive symptoms over 8 to 12 weeks, but this evidence is mostly of low or moderate quality due to imprecision of the estimates of effects. Augmentation with mirtazapine does not produce a clinically important benefit in reduction of depressive symptoms (high-quality evidence), and evidence regarding buspirone augmentation or switching to mianserin remains insufficient.

• Tolerability trade-offs limiting treatment adherence. Antipsychotic augmentation strategies are associated with a greater number of participants dropping out compared with antidepressant monotherapy — dropout rates ranged from 10% to 39% in antipsychotic-augmented groups, with the most common reasons being side effects or adverse events. In the VAST-D trial, augmentation with aripiprazole yielded only a modestly increased likelihood of remission (28.9%) versus switching to bupropion (22.3%), while adverse effects including somnolence, akathisia, and weight gain were more frequent in the aripiprazole group, raising questions about net clinical utility.

• Patient-level moderators are poorly characterized. The OPTIMUM trial (N = 742) found that augmentation was superior to switching only in older patients with fewer than three previous adequate antidepressant trials, with no other putative moderators — including age, executive dysfunction, comorbid medical burden, or comorbid anxiety — reaching significance. This underscores the limited ability to personalize treatment selection at the individual level.

• Absence of validated biomarkers for patient stratification. No single validated biomarker for identification of an immunometabolic phenotype currently exists, despite growing evidence implicating low-grade inflammation, immune dysregulation, and insulin resistance in TRD pathophysiology. Outcomes across clinical trials targeting these mechanisms have been inconsistent, attributed in part to limited stratification of participants based on underlying biology.

• Distinct neurobiological features of TRD remain incompletely understood. Patients with TRD demonstrate higher choroid plexus volumes, lower hippocampal volumes, and higher lateral ventricular volumes compared with both treatment-sensitive depression patients and healthy controls — findings that may reflect neuroinflammatory and trophic mechanisms specific to TRD. These structural differences were not observed between treatment-sensitive depression patients and healthy controls, suggesting TRD-specific neurobiological underpinnings that current treatment paradigms do not yet adequately address.

• Long-term efficacy and safety data are lacking. For both established pharmacological strategies and emerging rapid-acting agents such as ketamine and esketamine, data on long-term adverse events — including cystitis and misuse liability — remain insufficient. Further trials are needed to examine long-term effects of treatment, as well as the effectiveness of other pharmacological treatment strategies.

COMP360 and DT120: Clinical Validation and Regulatory Momentum

Recent clinical investigations into treatment-resistant depression (TRD) have evaluated both pharmacological and neuromodulatory interventions, offering comparative insights into efficacy and tolerability across distinct patient populations.

Reshaping the TRD Treatment Landscape with Psychedelic Therapies

Recent trial data have substantially broadened the therapeutic options available for treatment-resistant depression (TRD), moving well beyond conventional pharmacological augmentation and switching strategies. The OPTIMUM randomised controlled trial (N = 742), enrolling adults aged 60 years or older, established that augmentation is superior to antidepressant switching, but only in patients with fewer than three prior adequate antidepressant trials — a finding that underscores the diminishing returns of repeated pharmacological cycling and the need for alternative strategies in more refractory cases. A complementary systematic review and meta-analysis of five RCTs (4,480 patients) further refined this picture, demonstrating that aripiprazole augmentation (A-ARI) achieved a significantly higher response rate than bupropion augmentation (A-BUP) (RR: 1.15; 95% CI: 1.05, 1.25; P = 0.0007) and a significantly higher remission rate than switching to bupropion (S-BUP) (RR: 1.22; 95% CI: 1.00, 1.49; P = 0.05), while no significant difference in remission rate or MADRS improvement was observed between A-ARI and A-BUP.

Neuromodulatory and ketamine-based approaches have emerged as increasingly evidence-supported alternatives, particularly for patients who have exhausted pharmacological options. The ASCERTAIN-TRD randomised trial (N = 278) found that repetitive transcranial magnetic stimulation (rTMS) augmentation produced a significantly greater MADRS score change than antidepressant switching (score change −17.39 vs. −13.22; p = 0.015), whereas aripiprazole augmentation did not reach significance on that primary measure. Accelerated intermittent theta burst stimulation (ACC-iTBS) with the H1 coil demonstrated non-inferiority to standard high-frequency TMS at week 6 (HDRS-21 change: −19.02 vs. −19.79; between-group difference 0.76, p = 0.78), with a shorter median time to remission (21 vs. 28 days; p = 0.0324). In the ketamine space, a pilot study of intravenous ketamine in adults aged ≥60 years with TRD reported a 48% response rate, significant improvement in executive function (Cohen's d = 0.61), and no serious adverse events, while a meta-analysis of esketamine RCTs (nine trials; 1,449 patients) confirmed an improved clinical response rate (RR = 1.94) alongside dose-dependent adverse events — with dissociation risk ratios of 10.65 in the high-dose group (≥56 mg or 0.40 mg/kg) versus 3.27 in the low-dose group (≤28 mg or 0.20 mg/kg).

Serotonergic psychedelics represent the most novel frontier in the TRD landscape, with accumulating Phase 2 data supporting rapid and durable antidepressant effects. A randomised Phase 2 trial of a single 25-mg dose of synthetic psilocybin (N = 104) demonstrated a significantly greater reduction in MADRS scores compared with niacin placebo from baseline to day 43 (mean difference −12.3; 95% CI, −17.5 to −7.2; P < .001) and from baseline to day 8 (mean difference −12.0; 95% CI, −16.6 to −7.4; P < .001), with no serious treatment-emergent adverse events. A secondary analysis of psilocybin-assisted psychotherapy (PAP) in TRD (n = 30) further reported a statistically significant reduction in anhedonia on the Snaith-Hamilton Pleasure Scale at the 2-week primary endpoint (F(8, 143.48) = 3.43, p = 0.001), with clinically significant improvements sustained at 3-month and 6-month follow-up. Regulatory momentum in Australia, Switzerland, and Canada has begun to translate this evidence into clinical access, though the resource-intensive nature of psychedelic-assisted therapy — requiring specialised training and controlled settings — remains a meaningful barrier to broader implementation.

COMP360: A New Horizon for Treatment-Resistant Depression

The impending potential approval of Compass Pathways' COMP360 marks a pivotal moment for individuals grappling with treatment-resistant depression (TRD) and for the broader pharmaceutical landscape. For too long, patients with TRD have faced limited options, often enduring slow-acting treatments with suboptimal efficacy. COMP360, a psilocybin-based therapeutic, promises a significant shift, offering rapid and sustained antidepressant effects after a single administration, a stark contrast to the daily regimen and delayed onset of conventional therapies. This innovative approach, which integrates a pharmacological intervention with structured psychological support, has demonstrated "highly statistically significant" results in Phase 3 trials, positioning it as a potential game-changer.

However, the path to widespread adoption is not without its complexities. While psilocybin is generally well-tolerated in controlled clinical settings, common adverse events such as headache, nausea, and dizziness are reported. More critically, studies indicate that suicidal ideation or behavior has occurred in some participants, particularly non-responders, highlighting the absolute necessity for rigorous patient screening, continuous monitoring, and robust safety protocols. The integral role of specialized psychological support, while crucial for efficacy, also presents a significant logistical challenge. Scaling up a network of trained and certified therapists, along with establishing appropriate treatment environments, will be essential to ensure equitable access and consistent therapeutic outcomes.

Furthermore, while initial studies showed promising remission rates, larger Phase 2 trials have indicated more modest figures, suggesting that while symptom reduction is substantial, achieving sustained remission may require further refinement of treatment protocols or patient selection. Ongoing research exploring the administration of psilocybin alongside SSRIs or even without the full psychedelic experience could broaden its applicability and patient acceptability. As COMP360 moves closer to market, its success will not only depend on its clinical efficacy but also on the industry's ability to navigate these operational and safety considerations, ultimately shaping the future of mental health care.